AF
HRTX icon

Advisornet Financial’s Heron Therapeutics HRTX Stock Holding History

Advisornet Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88 Hold
110
– – ﹤0.01% 2205
2025
Q4 		$143 Hold
110
– – ﹤0.01% 2176
2025
Q3 		$139 Hold
110
– – ﹤0.01% 2175
2025
Q2 		$228 Hold
110
– – ﹤0.01% 2135
2025
Q1 		$242 Hold
110
– – ﹤0.01% 2059
2024
Q4 		$168 Hold
110
– – ﹤0.01% 1896
2024
Q3 		$219 Hold
110
– – ﹤0.01% 2114
2024
Q2 		$385 Hold
110
– – ﹤0.01% 1971
2024
Q1 		$305 Hold
110
– – ﹤0.01% 1927
2023
Q4 		$187 Hold
110
– – ﹤0.01% 2309
2023
Q3 		$113 Hold
110
– – ﹤0.01% 2205
2023
Q2 		$128 Hold
110
– – ﹤0.01% 2253
2023
Q1 		$166 Hold
110
– – ﹤0.01% 2275
2022
Q4 		$275 Hold
110
– – ﹤0.01% 2156
2022
Q3 		$0 Hold
110
– – ﹤0.01% 1931
2022
Q2 		$0 Hold
110
– – ﹤0.01% 1987
2022
Q1 		$1K Buy
+110
New +$805 ﹤0.01% 1888

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Advisornet Financial's HRTX Position: Q1 2026 in Review

Advisornet Financial held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 110 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #2205.

Advisornet Financial first reported a position in HRTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $1K in Q1 2022. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Advisornet Financial held 110 shares of Heron Therapeutics worth $88 as of Q1 2026.
  • Advisornet Financial left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Advisornet Financial's portfolio in Q1 2026, its #2205 holding.
  • Advisornet Financial first reported a position in Heron Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Advisornet Financial's Heron Therapeutics position peaked at $1K in Q1 2022.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Advisornet Financial's 13F filing for Q1 2026, filed 17 Apr 2026.